BridgeBio Pharma, Inc. (BBIO) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-11

Key Insights

CEO Kumar Neil executed a systematic sale of approximately 59,000 shares of BBIO common stock directly held between May 7-8, 2026, at prices ranging from $66.10 to $69.18 per share, generating roughly $4 million in proceeds through a pre-established Rule 10b5-1 trading plan adopted on March 31, 2025.
The filing reveals significant indirect holdings through two trusts (Kumar Haldea Family Irrevocable Trust and Kumar Haldea Revocable Trust) totaling approximately 8.9 million shares, with concurrent sales reducing trust holdings from ~600,000 to ~555,000 shares in the family irrevocable trust and ~4.4 million to ~4.35 million in the revocable trust.
The use of a pre-planned Rule 10b5-1 trading plan indicates the CEO's sales were pre-arranged and not based on material non-public information, which reduces concerns about negative signaling; however, the systematic liquidation pattern over two trading days suggests deliberate portfolio rebalancing or diversification rather than opportunistic selling.

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-13

Insider Neil Kumar sold a total of 59,000 shares of BridgeBio Pharma, Inc. (BBIO) stock on April 9-10, 2026, indicating some insider selling activity.
Kumar's sales were made pursuant to a Rule 10b5-1 sales plan, suggesting the transactions were pre-planned rather than opportunistic.
Kumar continues to hold a significant indirect beneficial ownership position of over 4.4 million shares through trusts, suggesting he retains a large stake in the company.

Filed: 2026-03-20

The reporting person, Thomas Trimarchi, acquired 59,041 shares of BridgeBio Pharma, Inc. (BBIO) common stock through a grant of restricted stock units (RSUs) under the company's equity incentive plan. This indicates insider ownership and alignment with shareholder interests.
The RSUs have a vesting schedule of 1/16th per quarter, suggesting a long-term incentive structure for the reporting person to remain with the company.
The reporting person's total beneficial ownership of BBIO common stock increased to 395,626 shares, representing a significant equity stake in the company.

Filed: 2026-03-20

The reporting person, Maricel Apuli, received a grant of 14,170 restricted stock units (RSUs) under the company's equity incentive plan, which will vest over time as she continues her service as Chief Accounting Officer.
The grant of RSUs represents an equity-based compensation award that aligns Apuli's interests with those of shareholders, as the value of her award will rise and fall with the company's stock price.
Insider transactions like this can provide insight into management's confidence in the company's future prospects, though the significance of a single RSU grant may be relatively modest.

Filed: 2026-03-19

Neil Kumar, the CEO of BridgeBio Pharma, has acquired 40,570 stock options and 104,313 restricted stock units, indicating his confidence in the company's future prospects.
The vesting schedule for the stock options and RSUs is structured to incentivize Kumar's long-term commitment, with 1/16th of the shares vesting quarterly over the next 4 years.
This insider transaction suggests that the CEO believes BridgeBio Pharma is well-positioned for growth, as he is increasing his personal stake in the company.

Filed: 2026-03-12

The reporting person, Hannah Valantine, exercised 8,671 stock options and immediately sold the same amount of shares, suggesting a desire to generate some liquidity.
The reported transaction was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-planned and systematic approach to the insider's trading activity.
The reporting person still holds a significant direct ownership stake of 16,136 shares, as well as an indirect stake of 398 shares held by their spouse, suggesting ongoing commitment to the company.

Filed: 2026-03-06

The reporting person, Andrea Ellis, is a director of BridgeBio Pharma, Inc. and has exercised 64,921 stock options and sold the same number of shares, potentially indicating a transaction under a pre-arranged 10b5-1 trading plan.
The reported transaction price of $64.8681 per share is higher than the exercise price of $8.45 per share, suggesting the director may have realized a significant gain from the transaction.
The remaining 18,589 shares still held by the director represent a relatively small ownership position, which could indicate that the director is diversifying their holdings or taking some cash off the table.

Filed: 2026-02-23

Insider Neil Kumar, the CEO, has sold a significant number of shares in BridgeBio Pharma, Inc. (BBIO) totaling over 27,000 shares in a single day.
The sales were executed pursuant to a pre-planned 10b5-1 trading plan, suggesting the transactions were not opportunistic.
Kumar retains a large indirect beneficial ownership of over 5 million shares in the company, indicating he remains heavily invested in BridgeBio's long-term success.

Filed: 2026-02-12

Neil Kumar, CEO of BridgeBio Pharma, has been actively selling shares in the company, disposing of over 46,000 shares in recent transactions.
Kumar's sales have been made pursuant to a pre-established 10b5-1 trading plan, suggesting the transactions may be part of a planned strategy rather than in response to new information.
The sales represent a relatively small portion of Kumar's overall holdings, as he continues to beneficially own over 4.5 million shares through various trusts for which he is a co-trustee.

Filed: 2026-01-12

Insider Neil Kumar has sold a significant amount of BridgeBio Pharma's (BBIO) common stock, totaling over 1.2 million shares across multiple transactions on January 8-9, 2026.
The sale transactions were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating the sales were likely part of a planned strategy rather than a reactive move.
The sales represent a substantial reduction in Kumar's beneficial ownership, from over 4.5 million shares to under 1 million shares, suggesting he may be seeking to diversify his personal portfolio.

Other reports for BridgeBio Pharma, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.